posted on 2018-04-20, 00:00authored byPrachi Singh, Stal Shrestha, Michelle Y. Cortes-Salva, Kimberly J. Jenko, Sami S. Zoghbi, Cheryl L. Morse, Robert B. Innis, Victor W. Pike
Cyclooxygenase-1
(COX-1) is a key enzyme in the biosynthesis of
proinflammatory thromboxanes and prostaglandins and is found in glial
and neuronal cells within brain. COX-1 expression is implicated in
numerous neuroinflammatory states. We aim to find a direct-acting
positron emission tomography (PET) radioligand for imaging COX-1 in
human brain as a potential biomarker of neuroinflammation and for
serving as a tool in drug development. Seventeen 3-substituted 1,5-diaryl-1H-1,2,4-triazoles were prepared as prospective COX-1 PET
radioligands. From this set, three 1,5-(4-methoxyphenyl)-1H-1,2,4-triazoles, carrying a 3-methoxy (5),
3-(1,1,1-trifluoroethoxy) (20), or 3-fluoromethoxy substituent
(6), were selected for radioligand development, based
mainly on their high affinities and selectivities for inhibiting human
COX-1, absence of carboxyl group, moderate computed lipophilicities,
and scope for radiolabeling with carbon-11 (t1/2 = 20.4 min) or fluorine-18 (t1/2 = 109.8 min). Methods were developed for producing [11C]5, [11C]20, and [d2-18F]6 from hydroxy precursors
in a form ready for intravenous injection for prospective evaluation
in monkey with PET.